Novartis LDE225 met primary endpoint in pivotal trial

Novartis announced that the pivotal trial of the investigational oral compound LDE225 in advanced basal cell carcinoma met its primary endpoint of demonstrating an objective response rate among patients within six months of treatment. Objective response included complete response, clinically significant tumor response with complete absence of disease, and partial response, clinically significant tumor shrinkage. Full study results will be presented at a future scientific meeting.

View Comments (0)